New Milton, UK, 29 September 2008 – Genetix Group plc (AIM: GTX) (“Genetix” or the “Company”), the cancer diagnostic and biopharmaceutical technologies group, today announces the appointment of Dr. Stephen Game as Head of Research and Development, a newly created position aimed at further strengthening the Company’s focus on innovation, with effect from 3rd November 2008.

Stephen will be responsible for Genetix’ R&D function, managing its expertise in software analysis, imaging, biology and robotics, and ensuring its R&D activities are aligned to market opportunities.

Stephen joins Genetix from GE Healthcare Life Sciences (GE) where he is currently a Technology Manager in Cellular Science. Stephen’s responsibilities include team management, strategic development and product portfolio management. Before GE acquired Amersham BioSciences, Stephen held a number of senior roles at Amersham – most recently as Department Director of Molecular Cell Biology, responsible for 35 staff and accountable for the strategic development of the department. Stephen holds a PhD in Biochemistry from the University of Bath.

Charles de Rohan, Chief Executive of Genetix, said: “With more than 17 years of industry experience, Stephen brings extensive knowledge and expertise to the business and is a strong addition to the Management Team. Stephen’s wideranging management and leadership skills will be of great value to Genetix as the Company continues to build its position in the fast-growing markets of biopharmaceutical drug discovery and cancer diagnostics.”